Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) EBIT (2016 - 2025)

Biomerica's EBIT history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBIT fell 38.27% year-over-year to -$1.4 million; the TTM value through Nov 2025 reached $914000.0, down 47.01%, while the annual FY2025 figure was $1.0 million, 16.28% down from the prior year.
  • EBIT for Q4 2025 was -$1.4 million at Biomerica, down from -$1.1 million in the prior quarter.
  • Across five years, EBIT topped out at $6.1 million in Q2 2024 and bottomed at -$2.2 million in Q1 2021.
  • The 5-year median for EBIT is -$1.5 million (2021), against an average of -$792226.4.
  • The largest annual shift saw EBIT crashed 1435.83% in 2023 before it surged 431.52% in 2024.
  • A 5-year view of EBIT shows it stood at -$1.1 million in 2021, then plummeted by 47.47% to -$1.7 million in 2022, then increased by 3.55% to -$1.6 million in 2023, then soared by 38.21% to -$993000.0 in 2024, then crashed by 38.27% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BMRA's EBIT are -$1.4 million (Q4 2025), -$1.1 million (Q3 2025), and $4.6 million (Q2 2025).